UBS AM
EPZM

UBS AM’s Epizyme, Inc EPZM Stock Holding History

UBS AM’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-182,293
Closed -$210K – 2819
2022
Q1 		$210K Buy
182,293
+81,004
+80% +$132K ﹤0.01% 2668
2021
Q4 		$253K Hold
101,289
– – ﹤0.01% 2715
2021
Q3 		$519K Hold
101,289
– – ﹤0.01% 2487
2021
Q2 		$842K Buy
101,289
+21,170
+26% +$178K ﹤0.01% 2306
2021
Q1 		$698K Buy
80,119
+8,902
+12% +$92.1K ﹤0.01% 2258
2020
Q4 		$773K Buy
71,217
+8,114
+13% +$100K ﹤0.01% 2110
2020
Q3 		$753K Sell
63,103
-5,858
-8% -$78.5K ﹤0.01% 1955
2020
Q2 		$1.11M Buy
68,961
+4,644
+7% +$81.1K ﹤0.01% 1751
2020
Q1 		$998K Sell
64,317
-5,369
-8% -$115K ﹤0.01% 1695
2019
Q4 		$1.71M Buy
69,686
+8,233
+13% +$122K ﹤0.01% 1665
2019
Q3 		$634K Buy
61,453
+16,518
+37% +$208K ﹤0.01% 2175
2019
Q2 		$564K Buy
44,935
+3,471
+8% +$44.7K ﹤0.01% 2160
2019
Q1 		$514K Buy
41,464
+4,832
+13% +$54K ﹤0.01% 2096
2018
Q4 		$226K Buy
36,632
+16,832
+85% +$129K ﹤0.01% 2339
2018
Q3 		$210K Hold
19,800
– – ﹤0.01% 2429
2018
Q2 		$268K Hold
19,800
– – ﹤0.01% 2349
2018
Q1 		$351K Buy
19,800
+9,600
+94% +$162K ﹤0.01% 2146
2017
Q4 		$128K Hold
10,200
– – ﹤0.01% 2373
2017
Q3 		$194K Hold
10,200
– – ﹤0.01% 2270
2017
Q2 		$154K Hold
10,200
– – ﹤0.01% 2289
2017
Q1 		$175K Buy
+10,200
New +$136K ﹤0.01% 2221
2015
Q3 		– Sell
-9,000
Closed -$216K – 2706
2015
Q2 		$216K Buy
+9,000
New +$173K ﹤0.01% 2551
2014
Q4 		– Sell
-173,800
Closed -$4.71M – 2634
2014
Q3 		$4.71M Sell
173,800
-59,168
-25% -$1.84M ﹤0.01% 1047
2014
Q2 		$7.25M Sell
232,968
-16,897
-7% -$398K 0.01% 948
2014
Q1 		$5.69M Sell
249,865
-10,323
-4% -$313K 0.01% 1009
2013
Q4 		$5.41M Sell
260,188
-3,882
-1% -$113K 0.01% 990
2013
Q3 		$10.6M Buy
264,070
+53,422
+25% +$1.81M 0.01% 789
2013
Q2 		$5.93M Buy
+210,648
New +$5.41M 0.01% 917

Other funds holding EPZM

RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS AM's EPZM Position: Q2 2022 in Review

UBS AM sold out of Epizyme, Inc (EPZM) in Q2 2022, closing a stake of 182,293 shares — an estimated $210K sold.

UBS AM first reported a position in EPZM in Q2 2013 and held it in 28 quarters. The position peaked at $10.6M in Q3 2013. 93 funds tracked by Wall St. Rank hold EPZM as of Q2 2022.

  • UBS AM reported no remaining Epizyme, Inc position as of Q2 2022 after selling out during the quarter.
  • UBS AM sold 182,293 Epizyme, Inc shares in Q2 2022, an estimated $210K.
  • UBS AM first reported a position in Epizyme, Inc in Q2 2013 and held it in 28 quarters.
  • UBS AM's Epizyme, Inc position peaked at $10.6M in Q3 2013.
  • 93 funds tracked by Wall St. Rank held Epizyme, Inc as of Q2 2022.

Based on UBS AM's 13F filing for Q2 2022, filed 12 Aug 2022.